Villy Valcheva, GH Research CEO

Irish start­up re­ports mid-stage vic­to­ry for short-act­ing psy­che­del­ic drug in de­pres­sion

GH Re­search has shared com­pelling da­ta in peo­ple with a tra­di­tion­al­ly chal­leng­ing form of de­pres­sion who were dosed with its psy­che­del­ic can­di­date, de­spite the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.